Putative CH TP53 variants

1. Poly(adp-ribose) polymerase inhibitor increases putative CH TP53 variants in humans (0/8 to 6/8 patients).

   Humansfirst-line platinum followed by PARP inhibitor maintenanceplasma cfDNAduring B2-B3femalesn = 8

   cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer

   Journal of gynecologic oncology·27 Jul 2026

More on Poly(adp-ribose) polymerase inhibitor